Discontinued — last reported Q4 '25
Vistra Interest Paid decreased by 3.8% to $202.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.8%, from $210.00M to $202.00M. This is a positive signal — lower values indicate better performance for this metric.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
interest_paid| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $159.00M | $159.00M | $159.00M | $159.00M | $246.75M | $246.75M | $246.75M | $246.75M | $210.00M | $202.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +55.2% | +0.0% | +0.0% | +0.0% | -14.9% | -3.8% |
| YoY Change | — | — | — | — | +55.2% | +55.2% | +55.2% | +55.2% | -14.9% | -3.8% |